Free Trial

Abbott Laboratories (ABT) Competitors

$102.19
+0.45 (+0.44%)
(As of 05/31/2024 ET)

ABT vs. PFE, NVS, ISRG, SYK, SNY, AZN, VRTX, BSX, MDT, and BDX

Should you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include Pfizer (PFE), Novartis (NVS), Intuitive Surgical (ISRG), Stryker (SYK), Sanofi (SNY), AstraZeneca (AZN), Vertex Pharmaceuticals (VRTX), Boston Scientific (BSX), Medtronic (MDT), and Becton, Dickinson and Company (BDX). These companies are all part of the "medical" sector.

Abbott Laboratories vs.

Pfizer (NYSE:PFE) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.

Abbott Laboratories has a net margin of 13.96% compared to Abbott Laboratories' net margin of -0.56%. Pfizer's return on equity of 20.18% beat Abbott Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer-0.56% 8.64% 3.70%
Abbott Laboratories 13.96%20.18%10.60%

In the previous week, Pfizer had 13 more articles in the media than Abbott Laboratories. MarketBeat recorded 35 mentions for Pfizer and 22 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 0.68 beat Pfizer's score of 0.54 indicating that Pfizer is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
19 Very Positive mention(s)
5 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Abbott Laboratories
10 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 1.1% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pfizer currently has a consensus target price of $35.86, indicating a potential upside of 25.11%. Abbott Laboratories has a consensus target price of $120.64, indicating a potential upside of 18.05%. Given Abbott Laboratories' higher possible upside, analysts plainly believe Pfizer is more favorable than Abbott Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
0 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40
Abbott Laboratories
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70

Pfizer received 569 more outperform votes than Abbott Laboratories when rated by MarketBeat users. However, 69.64% of users gave Abbott Laboratories an outperform vote while only 69.06% of users gave Pfizer an outperform vote.

CompanyUnderperformOutperform
PfizerOutperform Votes
1489
69.06%
Underperform Votes
667
30.94%
Abbott LaboratoriesOutperform Votes
920
69.64%
Underperform Votes
401
30.36%

Pfizer has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.9%. Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.2%. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 15 consecutive years and Abbott Laboratories has increased its dividend for 53 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

Abbott Laboratories has lower revenue, but higher earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$58.50B2.78$2.12B-$0.06-477.59
Abbott Laboratories$40.11B4.43$5.72B$3.2131.83

Summary

Abbott Laboratories beats Pfizer on 14 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABT vs. The Competition

MetricAbbott LaboratoriesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$177.77B$6.73B$5.13B$17.79B
Dividend Yield2.16%2.68%2.75%3.55%
P/E Ratio31.8322.62167.1725.81
Price / Sales4.43392.772,418.7811.40
Price / Cash15.9932.8835.3018.95
Price / Book4.556.085.535.90
Net Income$5.72B$138.60M$106.01M$976.46M
7 Day Performance-1.69%3.29%1.14%0.62%
1 Month Performance-3.86%1.09%1.43%4.79%
1 Year Performance-0.60%-1.29%4.07%24.00%

Abbott Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PFE
Pfizer
4.8113 of 5 stars
$28.68
+1.7%
$35.86
+25.0%
-24.6%$159.80B$58.50B-477.9288,000High Trading Volume
NVS
Novartis
2.2546 of 5 stars
$103.13
+2.4%
$116.67
+13.1%
+6.2%$205.83B$45.44B13.9276,057Analyst Forecast
Short Interest ↑
ISRG
Intuitive Surgical
4.3944 of 5 stars
$402.12
-0.3%
$403.67
+0.4%
+29.5%$143.08B$7.12B72.5813,676Analyst Forecast
Insider Selling
Short Interest ↑
SYK
Stryker
4.8529 of 5 stars
$340.85
+0.1%
$370.58
+8.7%
+22.4%$129.72B$20.50B38.9152,000Analyst Forecast
Positive News
SNY
Sanofi
2.9543 of 5 stars
$49.03
+2.5%
$55.00
+12.2%
-2.8%$121.00B$46.61B24.6486,088Short Interest ↓
Analyst Revision
AZN
AstraZeneca
3.3897 of 5 stars
$78.02
+1.6%
$88.00
+12.8%
+7.1%$238.02B$45.81B38.2589,900Analyst Forecast
Short Interest ↓
VRTX
Vertex Pharmaceuticals
4.04 of 5 stars
$455.34
+2.8%
$438.62
-3.7%
+40.7%$114.33B$9.87B29.555,400Analyst Forecast
Insider Selling
News Coverage
High Trading Volume
BSX
Boston Scientific
4.6139 of 5 stars
$75.59
+0.8%
$76.70
+1.5%
+46.7%$110.90B$14.24B63.5248,000Analyst Forecast
Insider Selling
Short Interest ↓
MDT
Medtronic
4.9252 of 5 stars
$81.39
+1.0%
$93.00
+14.3%
-1.7%$107.02B$32.36B29.6095,000Analyst Forecast
BDX
Becton, Dickinson and Company
4.8838 of 5 stars
$232.04
+2.3%
$280.17
+20.7%
-6.5%$67.06B$19.37B51.1173,000Analyst Forecast
Short Interest ↓
High Trading Volume

Related Companies and Tools

This page (NYSE:ABT) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners